Risk and outcomes of COVID-19 in patients with multiple sclerosis

Irene Moreno-Torres, Virginia Meca Lallana, Lucienne Costa-Frossard, Celia Oreja-Guevara, Clara Aguirre, Elda María Alba Suárez, Mayra Gómez Moreno, Laura Borrega Canelo, Julia Sabín Muñoz, Yolanda Aladro, Alba Cárcamo, Elena Rodríguez García, Juan Pablo Cuello, Enric Monreal , Susana Sainz de la Maza, Fernando Pérez Parra Pérez Parra, Francisco Valenzuela Rojas, Carlos López de Silanes de Miguel, Ignacio Casanova, Maria Luisa Martínez GinesRosario Blasco , Aida Orviz García, Luisa María Villar-Guimerans, Guillermo Fernández-Dono, Victor Elvira, Carmen Santiuste, Mercedes Espiño, José Manuel García Domínguez

Research output: Contribution to journalArticlepeer-review

Abstract / Description of output

Background and purpose: Limited information is available on incidence and outcomes of COVID-19 in patients with multiple sclerosis (MS). This study investigated the risks of SARS-CoV-2 infection and COVID-19-related outcomes in patients with MS, and compared these with the general population.

Methods: A regional registry was created to collect data on incidence, hospitalization rates, intensive care unit admission, and death in patients with MS and COVID-19. National government outcomes and seroprevalence data were used for comparison. The study was conducted at 14 specialist MS treatment centers in Madrid, Spain, between February and May 2020.

Results: Two-hundred nineteen patients were included in the registry, 51 of whom were hospitalized with COVID-19. The mean age ± standard deviation was 45.3 ± 12.4 years, and the mean duration of MS was 11.9 ± 8.9 years. The infection incidence rate was lower in patients with MS than the general population (adjusted incidence rate ratio = 0.78, 95% confidence interval [CI] = 0.70-0.80), but hospitalization rates were higher (relative risk = 5.03, 95% CI = 3.76-6.62). Disease severity was generally low, with only one admission to an intensive care unit and five deaths. Males with MS had higher incidence rates and risk of hospitalization than females. No association was found between the use of any disease-modifying treatment and hospitalization risk.
Original languageEnglish
Pages (from-to)3712-3721
Number of pages26
JournalEuropean Journal of Neurology
Issue number11
Early online date21 Jun 2021
Publication statusPublished - 30 Nov 2021


Dive into the research topics of 'Risk and outcomes of COVID-19 in patients with multiple sclerosis'. Together they form a unique fingerprint.

Cite this